Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
about
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerEGF receptor is required for KRAS-induced pancreatic tumorigenesisBiological approaches to therapy of pancreatic cancer.Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.Transforming growth factor alpha is a critical mediator of radiation lung injury.Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Targeting signal transduction in pancreatic cancer treatment.Molecular targeted therapies for pancreatic cancer.TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanismsHuman Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell linesNestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaMEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells.Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responseDelta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion.
P2860
Q28550689-E4D731BD-6E85-489A-97DD-8F46AD988AC1Q28584901-643C1F40-3907-4B20-B170-1C382F133C4DQ33899938-F59AA6B5-6AD5-4B5B-A2C0-D301A910E1E9Q33948775-10083DCF-ED54-468D-B7C7-9160E39F7AEEQ34213244-C66BAA60-66E6-4139-ACA3-B33777A649EEQ35691935-A18EA960-F163-4182-81F1-12B398C1555EQ36804444-373B4CBA-5248-4BA1-AE54-B58371244DD7Q36944441-EDC73445-6D57-47F6-A10B-AC0990BFDB11Q36956611-5536C0CE-B973-4F63-B325-6F74E52B3DB1Q36982771-B24033C6-FEDE-4EAD-9FB0-27CC5E2B91D1Q37124679-BA362B44-F748-44E6-AA68-80717D885222Q37351498-34C79605-D2F9-4D69-8DD7-1EB2FD5EE641Q37421053-84028C8D-99C5-4602-A719-E25741EE522CQ39799281-7AE52F22-62F3-4B82-81ED-83B30E44BC9BQ39894634-BAF044AA-2D52-462A-B542-B42D2E629F5AQ40176065-99BE4D05-9F9D-4AF5-9558-BC57BD945D60Q50909332-6FF064F7-9C0E-4BD5-A49D-839929EBF64C
P2860
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Transforming growth factor alp ...... pancreatic cancer cell lines.
@en
type
label
Transforming growth factor alp ...... pancreatic cancer cell lines.
@en
prefLabel
Transforming growth factor alp ...... pancreatic cancer cell lines.
@en
P2093
P1433
P1476
Transforming growth factor alp ...... pancreatic cancer cell lines.
@en
P2093
Cheryl H Baker
David J McConkey
Francesco Cognetti
Henry Q Xiong
James L Abbruzzese
Maria S Pino
Marissa Shrader
P304
P356
10.1158/0008-5472.CAN-05-3753
P407
P577
2006-04-01T00:00:00Z